Primary Sclerosing Cholangitis and Forecast Market
1 Introduction to Research & Analysis Reports
1.1 Primary Sclerosing Cholangitis (PSC) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Primary Sclerosing Cholangitis (PSC) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Primary Sclerosing Cholangitis (PSC) Overall Market Size
2.1 Global Primary Sclerosing Cholangitis (PSC) Market Size: 2022 VS 2029
2.2 Global Primary Sclerosing Cholangitis (PSC) Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Primary Sclerosing Cholangitis (PSC) Players in Global Market
3.2 Top Global Primary Sclerosing Cholangitis (PSC) Companies Ranked by Revenue
3.3 Global Primary Sclerosing Cholangitis (PSC) Revenue by Companies
3.4 Top 3 and Top 5 Primary Sclerosing Cholangitis (PSC) Companies in Global Market, by Revenue in 2022
3.5 Global Companies Primary Sclerosing Cholangitis (PSC) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Primary Sclerosing Cholangitis (PSC) Players in Global Market
3.6.1 List of Global Tier 1 Primary Sclerosing Cholangitis (PSC) Companies
3.6.2 List of Global Tier 2 and Tier 3 Primary Sclerosing Cholangitis (PSC) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Primary Sclerosing Cholangitis (PSC) Market Size Markets, 2022 & 2029
4.1.2 Medical Treatement
4.1.3 Liver Transplantation
4.1.4 Others
4.2 By Type - Global Primary Sclerosing Cholangitis (PSC) Revenue & Forecasts
4.2.1 By Type - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2023
4.2.2 By Type - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2024-2029
4.2.3 By Type - Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Primary Sclerosing Cholangitis (PSC) Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Primary Sclerosing Cholangitis (PSC) Revenue & Forecasts
5.2.1 By Application - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2023
5.2.2 By Application - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2024-2029
5.2.3 By Application - Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Primary Sclerosing Cholangitis (PSC) Market Size, 2022 & 2029
6.2 By Region - Global Primary Sclerosing Cholangitis (PSC) Revenue & Forecasts
6.2.1 By Region - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2023
6.2.2 By Region - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2024-2029
6.2.3 By Region - Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2029
6.3.2 US Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.3.3 Canada Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.3.4 Mexico Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2029
6.4.2 Germany Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.3 France Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.4 U.K. Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.5 Italy Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.6 Russia Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.7 Nordic Countries Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.8 Benelux Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2029
6.5.2 China Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.5.3 Japan Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.5.4 South Korea Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.5.5 Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.5.6 India Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2029
6.6.2 Brazil Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.6.3 Argentina Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2029
6.7.2 Turkey Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.7.3 Israel Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.7.4 Saudi Arabia Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.7.5 UAE Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
7 Primary Sclerosing Cholangitis (PSC) Companies Profiles
7.1 Acorda Therapeutics
7.1.1 Acorda Therapeutics Company Summary
7.1.2 Acorda Therapeutics Business Overview
7.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.1.4 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.1.5 Acorda Therapeutics Key News & Latest Developments
7.2 Gilead Sciences
7.2.1 Gilead Sciences Company Summary
7.2.2 Gilead Sciences Business Overview
7.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.2.4 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.2.5 Gilead Sciences Key News & Latest Developments
7.3 NGM Biopharmaceuticals
7.3.1 NGM Biopharmaceuticals Company Summary
7.3.2 NGM Biopharmaceuticals Business Overview
7.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.3.4 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.3.5 NGM Biopharmaceuticals Key News & Latest Developments
7.4 Intercept Pharmaceuticals
7.4.1 Intercept Pharmaceuticals Company Summary
7.4.2 Intercept Pharmaceuticals Business Overview
7.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.4.4 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.4.5 Intercept Pharmaceuticals Key News & Latest Developments
7.5 Dr. Falk Pharma
7.5.1 Dr. Falk Pharma Company Summary
7.5.2 Dr. Falk Pharma Business Overview
7.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.5.4 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.5.5 Dr. Falk Pharma Key News & Latest Developments
7.6 Allergan
7.6.1 Allergan Company Summary
7.6.2 Allergan Business Overview
7.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.6.4 Allergan Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.6.5 Allergan Key News & Latest Developments
7.7 Shire
7.7.1 Shire Company Summary
7.7.2 Shire Business Overview
7.7.3 Shire Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.7.4 Shire Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.7.5 Shire Key News & Latest Developments
7.8 Durect Corporation
7.8.1 Durect Corporation Company Summary
7.8.2 Durect Corporation Business Overview
7.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.8.4 Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.8.5 Durect Corporation Key News & Latest Developments
7.9 Conatus Pharmaceuticals
7.9.1 Conatus Pharmaceuticals Company Summary
7.9.2 Conatus Pharmaceuticals Business Overview
7.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.9.4 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.9.5 Conatus Pharmaceuticals Key News & Latest Developments
7.10 Sirnaomics
7.10.1 Sirnaomics Company Summary
7.10.2 Sirnaomics Business Overview
7.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.10.4 Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.10.5 Sirnaomics Key News & Latest Developments
7.11 Shenzhen HighTide Biopharmaceutical
7.11.1 Shenzhen HighTide Biopharmaceutical Company Summary
7.11.2 Shenzhen HighTide Biopharmaceutical Business Overview
7.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.11.4 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.11.5 Shenzhen HighTide Biopharmaceutical Key News & Latest Developments
7.12 Glenmark
7.12.1 Glenmark Company Summary
7.12.2 Glenmark Business Overview
7.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.12.4 Glenmark Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.12.5 Glenmark Key News & Latest Developments
7.13 Impax Laboratories
7.13.1 Impax Laboratories Company Summary
7.13.2 Impax Laboratories Business Overview
7.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.13.4 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.13.5 Impax Laboratories Key News & Latest Developments
7.14 Mylan
7.14.1 Mylan Company Summary
7.14.2 Mylan Business Overview
7.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.14.4 Mylan Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.14.5 Mylan Key News & Latest Developments
7.15 Teva Pharmaceuticals
7.15.1 Teva Pharmaceuticals Company Summary
7.15.2 Teva Pharmaceuticals Business Overview
7.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.15.4 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.15.5 Teva Pharmaceuticals Key News & Latest Developments
7.16 Daewoong Pharmaceutical
7.16.1 Daewoong Pharmaceutical Company Summary
7.16.2 Daewoong Pharmaceutical Business Overview
7.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.16.4 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.16.5 Daewoong Pharmaceutical Key News & Latest Developments
7.17 Mitsubishi Tanabe Pharma
7.17.1 Mitsubishi Tanabe Pharma Company Summary
7.17.2 Mitsubishi Tanabe Pharma Business Overview
7.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.17.4 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.17.5 Mitsubishi Tanabe Pharma Key News & Latest Developments
7.18 Lannett
7.18.1 Lannett Company Summary
7.18.2 Lannett Business Overview
7.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.18.4 Lannett Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.18.5 Lannett Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Primary Sclerosing Cholangitis (PSC) Market Opportunities & Trends in Global Market
Table 2. Primary Sclerosing Cholangitis (PSC) Market Drivers in Global Market
Table 3. Primary Sclerosing Cholangitis (PSC) Market Restraints in Global Market
Table 4. Key Players of Primary Sclerosing Cholangitis (PSC) in Global Market
Table 5. Top Primary Sclerosing Cholangitis (PSC) Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Primary Sclerosing Cholangitis (PSC) Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Primary Sclerosing Cholangitis (PSC) Revenue Share by Companies, 2018-2023
Table 8. Global Companies Primary Sclerosing Cholangitis (PSC) Product Type
Table 9. List of Global Tier 1 Primary Sclerosing Cholangitis (PSC) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Primary Sclerosing Cholangitis (PSC) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Primary Sclerosing Cholangitis (PSC) Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Primary Sclerosing Cholangitis (PSC) Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Primary Sclerosing Cholangitis (PSC) Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Primary Sclerosing Cholangitis (PSC) Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2024-2029
Table 30. Acorda Therapeutics Company Summary
Table 31. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 32. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 33. Acorda Therapeutics Key News & Latest Developments
Table 34. Gilead Sciences Company Summary
Table 35. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 36. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 37. Gilead Sciences Key News & Latest Developments
Table 38. NGM Biopharmaceuticals Company Summary
Table 39. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 40. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 41. NGM Biopharmaceuticals Key News & Latest Developments
Table 42. Intercept Pharmaceuticals Company Summary
Table 43. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 44. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 45. Intercept Pharmaceuticals Key News & Latest Developments
Table 46. Dr. Falk Pharma Company Summary
Table 47. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 48. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 49. Dr. Falk Pharma Key News & Latest Developments
Table 50. Allergan Company Summary
Table 51. Allergan Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 52. Allergan Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 53. Allergan Key News & Latest Developments
Table 54. Shire Company Summary
Table 55. Shire Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 56. Shire Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 57. Shire Key News & Latest Developments
Table 58. Durect Corporation Company Summary
Table 59. Durect Corporation Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 60. Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 61. Durect Corporation Key News & Latest Developments
Table 62. Conatus Pharmaceuticals Company Summary
Table 63. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 64. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 65. Conatus Pharmaceuticals Key News & Latest Developments
Table 66. Sirnaomics Company Summary
Table 67. Sirnaomics Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 68. Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 69. Sirnaomics Key News & Latest Developments
Table 70. Shenzhen HighTide Biopharmaceutical Company Summary
Table 71. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 72. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 73. Shenzhen HighTide Biopharmaceutical Key News & Latest Developments
Table 74. Glenmark Company Summary
Table 75. Glenmark Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 76. Glenmark Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 77. Glenmark Key News & Latest Developments
Table 78. Impax Laboratories Company Summary
Table 79. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 80. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 81. Impax Laboratories Key News & Latest Developments
Table 82. Mylan Company Summary
Table 83. Mylan Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 84. Mylan Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 85. Mylan Key News & Latest Developments
Table 86. Teva Pharmaceuticals Company Summary
Table 87. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 88. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 89. Teva Pharmaceuticals Key News & Latest Developments
Table 90. Daewoong Pharmaceutical Company Summary
Table 91. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 92. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 93. Daewoong Pharmaceutical Key News & Latest Developments
Table 94. Mitsubishi Tanabe Pharma Company Summary
Table 95. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 96. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 97. Mitsubishi Tanabe Pharma Key News & Latest Developments
Table 98. Lannett Company Summary
Table 99. Lannett Primary Sclerosing Cholangitis (PSC) Product Offerings
Table 100. Lannett Primary Sclerosing Cholangitis (PSC) Revenue (US$, Mn) & (2018-2023)
Table 101. Lannett Key News & Latest Developments
List of Figures
Figure 1. Primary Sclerosing Cholangitis (PSC) Segment by Type in 2022
Figure 2. Primary Sclerosing Cholangitis (PSC) Segment by Application in 2022
Figure 3. Global Primary Sclerosing Cholangitis (PSC) Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Primary Sclerosing Cholangitis (PSC) Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Primary Sclerosing Cholangitis (PSC) Revenue in 2022
Figure 8. By Type - Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
Figure 9. By Application - Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
Figure 10. By Type - Global Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
Figure 12. By Application - Global Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
Figure 14. By Region - Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
Figure 15. By Country - North America Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
Figure 16. US Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
Figure 20. Germany Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 21. France Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
Figure 28. China Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 32. India Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
Figure 34. Brazil Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
Figure 37. Turkey Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Primary Sclerosing Cholangitis (PSC) Revenue, (US$, Mn), 2018-2029
Figure 41. Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Allergan Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Shire Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Glenmark Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Mylan Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Lannett Primary Sclerosing Cholangitis (PSC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Industry Market Size
